InteKrin Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for diabetes, obesity and metabolic disorders.  InteKrin in-licenses high potential clinical stage products from large biotechnology and pharmaceutical companies, and then carries them through to critical clinical stages.  InteKrin's lead drug candidate, INT131, an insulin sensitizer targeted to Type II diabetes, is in Phase IIb clinical trials.